The World Health Organization (WHO) added cardiovascular polypills to its 2023 Model List of Essential Medicines, and research continues to show that these medications are effective at preventing atherosclerotic cardiovascular disease (ACD) among various other forms of cardiovascular disease. Yet experts say obstacles remain to the adoption of these medications in high-income developed nations.
Barriers Remain to Widespread Use of Polypills for CVD Therapy in High-Income Nations As Testing Continues
View Content